Medizinische Universität Graz - Research portal
Moik Florian |
** = Publications listed in SCI/SSCI/Pubmed
2025
Full paper/article (Journal)
** Englisch, C; Nopp, S; Moik, F; Starzer, AM; Quehenberger, P; Preusser, M; Berghoff, AS; Ay, C; Pabinger, I
The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.
ESMO Open. 2025; 10(2): 104130
Doi: 10.1016/j.esmoop.2024.104130
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Absenger, G; Wurm, R; Hochmair, MJ; Ay, C
Prevention and Treatment of Venous Thromboembolism Associated with Amivantamab-Based Therapies in Patients with Lung Cancer-Provisional Clinical Opinion Based on Existing Clinical Practice Guidelines.
Cancers (Basel). 2025; 17(2):
Doi: 10.3390/cancers17020259
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Terbuch, A; Sprakel, A; Pichler, G; Barth, DA; Pichler, R; Rainer, P; Silbernagel, G; Mannweiler, S; Jost, PJ; Ahyai, SA; Bauernhofer, T; Hutterer, GC; Pichler, M
Arterial thromboembolic events in testicular cancer patients: short- and long-term incidence, risk factors, and impact on mortality.
J Thromb Haemost. 2025;
Doi: 10.1016/j.jtha.2025.01.022
PubMed
FullText
FullText_MUG
** Verso, M; Moik, F; Graziani, M; Cohen, AT
Response to Comment on: "Targeted anti-cancer agents and risk of venous thromboembolism".
Haematologica. 2025;
Doi: 10.3324/haematol.2025.287998
PubMed
FullText
FullText_MUG
2024
Full paper/article (Journal)
** Englisch, C; Moik, F; Steiner, D; Starzer, AM; Berghoff, AS; Preusser, M; Pabinger, I; Ay, C
Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study.
Blood. 2024; 144(22):2349-2359
Doi: 10.1182/blood.2024025362
Web of Science
PubMed
FullText
FullText_MUG
** Englisch, C; Moik, F; Thaler, J; Koder, S; Mackman, N; Preusser, M; Pabinger, I; Ay, C
Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.
Haematologica. 2024; 109(4):1128-1136
Doi: 10.3324/haematol.2023.283581
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Englisch, C; Nopp, S; Moik, F; Steiner, D; Starzer, AM; Fritzer-Szekeres, M; Preusser, M; Berghoff, AS; Pabinger, I; Ay, C
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients: Results From the Vienna CAT-BLED Study.
JACC CardioOncol. 2025; 7(2):141-152
Doi: 10.1016/j.jaccao.2024.11.007
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Kraler, S; Liberale, L; Nopp, S; Englisch, C; Grilz, E; Lapikova-Bryhinska, T; Akhmedov, A; Carbone, F; Ramoni, D; Tirandi, A; Scuricini, A; Isoppo, S; Tortorella, C; La, Rosa, F; Michelauz, C; Frè, F; Gavoci, A; Lisa, A; Suter, TM; von, Eckardstein, A; Wenzl, FA; Pabinger, I; Lüscher, TF; Montecucco, F; Ay, C; Moik, F
Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study.
J Thromb Haemost. 2024; 22(11):3125-3136
Doi: 10.1016/j.jtha.2024.07.019
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Riedl, JM; Barth, D; Berton, F; Fink, M; Englisch, C; Hoeller, C; Fuereder, T; Ay, L; Pabinger, I; Richtig, E; John, N; Kostmann, SM; Jost, PJ; Gerger, A; Terbuch, A; Preusser, M; Ay, C
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors
JACC-CARDIOONCOL. 2024; 6(6): 965-975.
Doi: 10.1016/j.jaccao.2024.09.007
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Review
** Moik, F; Ay, C
Treatment of VTE in the thrombocytopenic cancer patient.
Hematology Am Soc Hematol Educ Program. 2024; 2024(1): 259-269.
Doi: 10.1182/hematology.2024000551
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Riedl, JM; Englisch, C; Ay, C
Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies.
Hamostaseologie. 2024; 44(1):40-48
Doi: 10.1055/a-2215-9909
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Moik, F; Esterl, T; Kostmann, SM; Gerger, A; Jost, PJ
Molecular diagnostics tailoring personalized cancer therapy-an oncologist's view.
Virchows Arch. 2024; 484(2):169-179
Doi: 10.1007/s00428-023-03702-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Verso, M; Moik, F; Graziani, M; Cohen, AT
Targeted anti-cancer agents and risk of venous thromboembolism.
Haematologica. 2024; 109(12): 3868-3878.
Doi: 10.3324/haematol.2023.284778
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Moik, F; Riedl, JM; Edlinger, L; Esterl, T; Hasenleithner, S; Kostmann, S; Cebular, L; Jahn, S; Kashofer, K; Zacharias, M; Hoefler, G; Heitzer, E; Gerger, A; Jost, PJ
Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
ANN ONCOL. 2024; 35: S262-S263.
Doi: 10.1016/j.annonc.2024.08.130
Web of Science
FullText
FullText_MUG
** Seeber, A; Huemer, F; Doleschal, B; Taghizadeh, H; Reimann, P; Moik, F; Kostmann, S; Wagner, L; Granitzer, J; Hamid, MA; Bachleitner, C; Amann, A; Wolf, D; Greil, R; Jost, PJ; Winder, T; Rumpold, H; Weiss, L; Gerger, A; Riedl, JM
Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
ANN ONCOL. 2024; 35: S445-S446.
Doi: 10.1016/j.annonc.2024.08.599
Web of Science
FullText
FullText_MUG
Comment
** Moik, F; Riedl, JM; Ay, C
VTE with Amivantamab plus Chemotherapy in NSCLC.
N Engl J Med. 2024; 390(6): 578-579.
Doi: 10.1056/NEJMc2314937
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Riedl, JM; Ay, C
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Ann Oncol. 2024; 35(3):327
Doi: 10.1016/j.annonc.2023.11.007
Web of Science
PubMed
FullText
FullText_MUG
2023
Full paper/article (Journal)
** Ay, C; Grilz, E; Nopp, S; Moik, F; Königsbrügge, O; Klimek, P; Thurner, S; Posch, F; Pabinger, I
Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study.
Res Pract Thromb Haemost. 2023; 7(1): 100026
Doi: 10.1016/j.rpth.2022.100026
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Moik, F; Steinlechner, S; Posch, F; Mayer, MC; Sandner, AM; Berton, F; Schlintl, V; Koch, L; John, N; Wurm, R; Pichler, M; Bauernhofer, T; Reimann, P; Wohlkönig, C; Richtig, E; Winder, T; Preusser, M; Jost, PJ; Ay, C; Gerger, A; Terbuch, A; Riedl, JM
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
J Immunother Cancer. 2023; 11(12):
Doi: 10.1136/jitc-2023-007765
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Kraemmer, D; Königsbrügge, O; Moik, F; Wildner, B; Ay, C; Pabinger, I
Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis.
J Thromb Haemost. 2023; 21(12): 3432-3449.
Doi: 10.1016/j.jtha.2023.08.031
Web of Science
PubMed
FullText
FullText_MUG
** Mauracher, LM; Hell, L; Moik, F; Krall, M; Englisch, C; Roiß, J; Grilz, E; Hofbauer, TM; Brostjan, C; Knapp, S; Ay, C; Pabinger, I
Neutrophils in lung cancer patients: Activation potential and neutrophil extracellular trap formation.
Res Pract Thromb Haemost. 2023; 7(2):100126
Doi: 10.1016/j.rpth.2023.100126
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Nopp, S; Moik, F; Kraler, S; Englisch, C; Preusser, M; von, Eckardstein, A; Pabinger, I; Lüscher, TF; Ay, C
Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
J Thromb Haemost. 2023; 21(9):2461-2472
Doi: 10.1016/j.jtha.2023.04.043
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Barth, D; Moik, F; Steinlechner, SM; Posch, F; Schlintl, V; Koch, L; John, N; Wurm, R; Pichler, M; Bauernhofer, T; Reimann, P; Wohlkönig, C; Richtig, E; Winder, T; Preusser, M; Jost, PJ; Ay, C; Gerger, A; Terbuch, A; Riedl, JM
Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
ANN ONCOL. 2023; 34: S259-S259.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.2917
[Poster]
Web of Science
FullText
FullText_MUG
** Riedl, JM; Steinlechner, SM; Moik, F; Heitzer, E; Jahn, S; Hasenleithner, S; Doleschal, B; Weiss, L; Seeber, A; Rumpold, H; Winder, T; Greil, R; Jost, PJ; Hoefler, G; Speicher, M; Gerger, A
SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvagetherapy matching in patients with advanced and refractory carcinoma
ANN ONCOL. 2023; 34: S1186-S1186.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Barcelona, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1349
[Poster]
Web of Science
FullText
FullText_MUG
2022
Full paper/article (Journal)
** Englisch, C; Königsbrügge, O; Nopp, S; Moik, F; Quehenberger, P; Preusser, M; Pabinger, I; Ay, C
Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer.
Int J Mol Sci. 2022; 23(24):
Doi: 10.3390/ijms232415770
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Englisch, C; Moik, F; Nopp, S; Raderer, M; Pabinger, I; Ay, C
ABO blood group type and risk of venous thromboembolism in patients with cancer
BLOOD ADV. 2022; 6(24): 6274-6281.
Doi: 10.1182/bloodadvances.2021006283
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Colling, M; Mahé, I; Jara-Palomares, L; Pabinger, I; Ay, C
Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review.
J THROMB HAEMOST. 2022; 20(3): 619-634.
Doi: 10.1111/jth.15599
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Nopp, S; Moik, F; Klok, FA; Gattinger, D; Petrovic, M; Vonbank, K; Koczulla, AR; Ay, C; Zwick, RH
Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life.
Respiration. 2022; 1-9.
Doi: 10.1159/000522118
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Posch, F; Niedrist, T; Glantschnig, T; Firla, S; Moik, F; Kolesnik, E; Wallner, M; Verheyen, N; Jost, PJ; Zirlik, A; Pichler, M; Balic, M; Rainer, PP
Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer.
Front Cardiovasc Med. 2022; 9: 933428
Doi: 10.3389/fcvm.2022.933428
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
Review
** Khorana, AA; Mackman, N; Falanga, A; Pabinger, I; Noble, S; Ageno, W; Moik, F; Lee, AYY
Cancer-associated venous thromboembolism.
Nat Rev Dis Primers. 2022; 8(1): 11
Doi: 10.1038/s41572-022-00336-y
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Ay, C
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies
THROMB RES. 2022; 213: S58-S65.
Doi: 10.1016/j.thromres.2022.01.004
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Ay, C
Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer.
J Thromb Haemost. 2022; 20(12):2733-2745
Doi: 10.1111/jth.15880
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Sanfilippo, KM; Moik, F; Candeloro, M; Ay, C; Di Nisio, M; Lee, AYY
Unanswered questions in cancer-associated thrombosis
BRIT J HAEMATOL. 2022;
Doi: 10.1111/bjh.18276
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Englisch, C; Konigsbrugge, O; Moik, F; Quehenberger, P; Preusser, M; Pabinger, I; Ay, C
Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer
THROMB RES. 2022; 213: S12-S12.-11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); MAY 27-29, 2022; Bergamo, ITALY.
[Oral Communication]
Web of Science
** Moik, F; Kraler, S; Montecucco, F; Liberale, L; Nopp, S; Englisch, C; Lapikova-Bryhinska, T; Akhmedov, A; von Eckardstein, A; Wenzl, FA; Pabinger, I; Luscher, TF; Ay, C
Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer
BLOOD. 2022; 140: 1255-1256.
Doi: 10.1182/blood-2022-163287
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Troelsen, FS; Vago, EK; Horvath-Puho, E; van Es, N; Mulder, FI; Moik, F; Erichsen, R; Ay, C; Sorensen, HT
KRAS mutation in colorectal cancer and risk of venous thromboembolism: a Danish population-based cohort study
THROMB RES. 2022; 213: S11-S11.-11th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC); MAY 27-29, 2022; Bergamo, ITALY.
[Oral Communication]
Web of Science
2021
Full paper/article (Journal)
** Ercan, H; Mauracher, LM; Grilz, E; Hell, L; Hellinger, R; Schmid, JA; Moik, F; Ay, C; Pabinger, I; Zellner, M
Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.
Cancers (Basel). 2021; 13(9):
Doi: 10.3390/cancers13092260
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Hisada, Y; Garratt, KB; Maqsood, A; Grover, SP; Kawano, T; Cooley, BC; Erlich, J; Moik, F; Flick, MJ; Pabinger, I; Mackman, N; Ay, C
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Blood Adv. 2021; 5(2):487-495
Doi: 10.1182/bloodadvances.2020003149
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Chan, WE; Wiedemann, S; Hoeller, C; Tuchmann, F; Aretin, MB; Fuereder, T; Zöchbauer-Müller, S; Preusser, M; Pabinger, I; Ay, C
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Blood. 2021; 137(12):1669-1678
Doi: 10.1182/blood.2020007878
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Prager, G; Thaler, J; Posch, F; Wiedemann, S; Schramm, T; Englisch, C; Mackman, N; Pabinger, I; Ay, C
Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Arterioscler Thromb Vasc Biol. 2021; 41(11): 2837-2847.
Doi: 10.1161/ATVBAHA.121.316463
Web of Science
PubMed
FullText
FullText_MUG
** Mollnar, S; Pondorfer, P; Kasparek, AK; Reinisch, S; Moik, F; Stotz, M; Halm, M; Szkandera, J; Terbuch, A; Eisner, F; Gerger, A; Kapp, KS; Partl, R; Vasicek, S; Weiland, T; Pichler, M; Stöger, H; Thurnher, D; Posch, F
Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy.
Clin Transl Oncol. 2021; 23(3):543-553
Doi: 10.1007/s12094-020-02447-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Mulder, FI; Horváth-Puhó, E; van, Es, N; van, Laarhoven, HWM; Pedersen, L; Moik, F; Ay, C; Büller, HR; Sørensen, HT
Venous thromboembolism in cancer patients: a population-based cohort study.
Blood. 2021; 137(14):1959-1969
Doi: 10.1182/blood.2020007338
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151:3-13
Doi: 10.1016/j.ejca.2021.03.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Review
** Moik, F; Makatsariya, A; Ay, C
Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia - A case-based review of clinical management.
Thromb Res. 2021; 199:38-42
Doi: 10.1016/j.thromres.2020.12.016
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Moik, F; van Es, N; Posch, F; Di Nisio, M; Fureder, T; Preusser, M; Pabinger, I; Ay, C
Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study
THROMB RES. 2021; 200: S68-S69.
[Poster]
Web of Science
FullText
2020
Full paper/article (Journal)
** Fuereder, T; Berghoff, AS; Heller, G; Haslacher, H; Perkmann, T; Strassl, R; Berger, JM; Puhr, HC; Kreminger, J; Moik, F; Schubert, L; Starzer, AM; Steindl, A; Winkler, S; Preusser, M; Tobudic, S
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
ESMO Open. 2020; 5(5):e000889
Doi: 10.1136/esmoopen-2020-000889
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klöckl, MC; Kasparek, AK; Riedl, JM; Moik, F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer, T; Schilcher, G; Zitta, S; Rosenkranz, AR; Friedl, C; Stöger, H; Posch, F
Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
Sci Rep. 2020; 10(1):11219
Doi: 10.1038/s41598-020-68010-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Mir, Seyed, Nazari, P; Berghoff, AS; Preusser, M; Moik, F; Posch, F; Ricken, G; Riedl, J; Hell, L; Marosi, C; Hainfellner, JA; Pabinger, I; Ay, C
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma.
ESMO Open. 2020; 5(3):e000647
Doi: 10.1136/esmoopen-2019-000647
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.
Thromb Res. 2020; 187:9-17
Doi: 10.1016/j.thromres.2020.01.002
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Posch, F; Zielinski, C; Pabinger, I; Ay, C
Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials.
Res Pract Thromb Haemost. 2020; 4(4):550-561
Doi: 10.1002/rth2.12359
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; van, Es, N; Posch, F; Di, Nisio, M; Fuereder, T; Preusser, M; Pabinger, I; Ay, C
Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study.
Cancers (Basel). 2020; 12(9):
Doi: 10.3390/cancers12092493
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Zöchbauer-Müller, S; Posch, F; Pabinger, I; Ay, C
Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer.
Cancers (Basel). 2020; 12(6):
Doi: 10.3390/cancers12061619
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Nopp, S; Klok, FA; Moik, F; Petrovic, M; Derka, I; Ay, C; Zwick, RH
Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism.
J Clin Med. 2020; 9(6):
Doi: 10.3390/jcm9061811
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Nopp, S; Moik, F; Jilma, B; Pabinger, I; Ay, C
Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis.
Res Pract Thromb Haemost. 2020;
Doi: 10.1002/rth2.12439
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Review
** Moik, F; Ay, C
How I Manage Cancer-Associated Thrombosis.
Hamostaseologie. 2020; 40(1):38-46
Doi: 10.1055/s-0039-3402806
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Ay, C; Pabinger, I
Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future.
Thromb Res. 2020; 191 Suppl 1:S3-S11
Doi: 10.1016/S0049-3848(20)30389-3
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Pabinger, I; Ay, C
How I treat cancer-associated thrombosis.
ESMO Open. 2020; 5(1):e000610
Doi: 10.1136/esmoopen-2019-000610
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
** Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
2019
Full paper/article (Journal)
** Mir, Seyed, Nazari, P; Marosi, C; Moik, F; Riedl, J; Özer, Ö; Berghoff, AS; Preusser, M; Hainfellner, JA; Pabinger, I; Zlabinger, GJ; Ay, C
Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma.
Cancers (Basel). 2019; 11(12):
Doi: 10.3390/cancers11122020
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Riedl, JM; Winder, T; Terbuch, A; Rossmann, CH; Szkandera, J; Bauernhofer, T; Kasparek, AK; Schaberl-Moser, R; Reicher, A; Prinz, F; Pichler, M; Stöger, H; Stotz, M; Gerger, A; Posch, F
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Sci Rep. 2019; 9(1):5548
Doi: 10.1038/s41598-019-42069-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Glantschnig, T; Posch, F; Firla, S; Moik, F; Ablasser, K; Binder, JS; Stoschitzky, G; Wallner, M; Von Lewinski, D; Stoger, H; Zirlik, A; Pichler, M; Rainer, PP
Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
WIEN KLIN WOCHENSCHR. 2019; 131: 292-293.
[Poster]
Web of Science
** Posch, F; Glantschnig, T; Firla, S; Smolle, M; Balic, M; Moik, F; Stoeger, H; Zirlik, A; Pichler, M; Rainer, P
Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
EUR HEART J. 2019; 40: 3844-3844.-ESC Congress / World Congress of Cardiology; AUG 31-SEP 04, 2019; Paris, FRANCE.
[Poster]
Web of Science
2018
Abstract (Journal)
** Mollnar, S; Pondorfer, P; Reinisch, S; Moik, F; Halm, M; Kasparek, AK; Klockl, MC; Stotz, M; Szkandera, J; Gerger, A; Vasicek, S; Weiland, T; Pichler, M; Stoger, H; Thurnher, D; Posch, F
Definitive chemoradiotherapy with or without induction chemotherapy for unresectable squamous cell carcinoma of the head & neck: a propensity-score analysis
ONCOL RES TREAT. 2018; 41: 248-248.
[Poster]
Web of Science
Abstract (Proceedings)
** Klöckl, MC; Kasparek, AK; Riedl, J; Moik ,F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer T; Stöger H; Posch, F
Estimated versus measured glomerular filtration rate to
evaluate kidney function in patients with cancer undergoing
cisplatin-based chemotherapy
Oncology Research
and Treatment . 2018; 41(Suppl4):224-224.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 28- OCT 2, 2018; Vienna, AUSTRIA. (ISBN: 978-3-318-06425-4 )
[Poster]
Web of Science
FullText
2017
Full paper/article (Journal)
** Riedl, JM; Posch, F; Moik, F; Bezan, A; Szkandera, J; Smolle, MA; Kasparek, AK; Pichler, M; Stöger, H; Stotz, M; Gerger, A
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting.
Oncotarget. 2017; 8(56):96048-96061
Doi: 10.18632/oncotarget.21647
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG